AspenBio Pharma Reports Second Quarter 20...(inally anticipated to complete this has ...)

Date:8/20/2007

inally anticipated to complete, this has allowed us to fine tune specific aspects of blood collection as well as the practical use of the test in a hospital clinical setting. The company is currently engaged with multiple hospital sites for the collection of additional trial samples.

AspenBio has also commenced initial steps for the U.S. FDA approval process for AppyScore with the engagement of three widely recognized FDA device registration consultants to assist with the process. The company expects an initial meeting with the FDA on the AppyScore Appendicitis Triage Blood Test to occur within the next thirty to forty-five days. AspenBio has also executed contracts with FDA-approved diagnostic test manufacturers related to assay development, GMP manufacturing, and validation of different versions of the first generation AppyScore and AppyScreen test formats. The on-going 400 patient pre-FDA trial is anticipated to be completed by the end of September, with an announcement of the data planned shortly after completion. These activities, if successfully completed, put the first generation of AppyScore on a timeline for introduction in the United States in 2008.

BoviPure FSH: AspenBio Pharma announced in July it had filed and received an INADA file number for BoviPure FSH (bovine follicle stimulating hormone) to officially start the FDA approval process. Additionally, in order to facilitate the product advancement, AspenBio also executed a contract with AppTec Laboratory Services, Inc. ("AppTec") for the required GMP manufacturing and validation of this product. This advancement follows a similar path that commenced in January for StayBred(TM) (a/k/a BoviPure LH(TM), an LH analog for cows), AspenBio's largest market potential, single-chain, reproduction- enhancing drug.

BoviPure FSH, the company's second largest market potential livestock drug, is currently advancing ahead of schedule with the initiation of the FDA approval process. This drug is desig
'/>"/>

SOURCE AspenBio Pharma, Inc. Copyright©2007 PR Newswire.

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango